Dasiglucagon in rescue pen: Phase II data

A double-blind, crossover, German Phase II trial in 58 Type I diabetics with severe hypoglycemia showed that all patients who received single doses of 0.3, 0.6 and 1 mg subcutaneous dasiglucagon or wh...